An Analysis of the Results of the BETH Study
Adam Brufsky, MD, PhD, FACP, professor of medicine, associate division chief, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, discusses the results of the BETH study
Adam Brufsky, MD, PhD, FACP, professor of medicine, associate division chief, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, discusses the results of the BETH study, which compared chemotherapy plus trastuzumab versus chemotherapy plus trastuzumab plus bevacizumab in patients with HER2-positive breast cancer.
Clinical Pearls:
- Although the results of the trial were negative, the results did show that THC therapy is as good, if not better, than ACTH therapy
- The results of the BETH study are consistent with other studies
- The era of adjuvant bevacizumab for breast cancer has come and gone unless there is a way to select patients who will benefit
- Some biomarkers are in the works that may be able to be used to select patients who will benefit from bevacizumab
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
